367 related articles for article (PubMed ID: 30593409)
1. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis.
van der Graaff D; Kwanten WJ; Francque SM
Med Hypotheses; 2019 Jan; 122():188-197. PubMed ID: 30593409
[TBL] [Abstract][Full Text] [Related]
2. Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD.
van der Graaff D; Chotkoe S; De Winter B; De Man J; Casteleyn C; Timmermans JP; Pintelon I; Vonghia L; Kwanten WJ; Francque S
JHEP Rep; 2022 Feb; 4(2):100412. PubMed ID: 35036886
[TBL] [Abstract][Full Text] [Related]
3. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
4. Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease.
Sundaram SS; Halbower A; Pan Z; Robbins K; Capocelli KE; Klawitter J; Shearn CT; Sokol RJ
J Hepatol; 2016 Sep; 65(3):560-9. PubMed ID: 27501738
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
[TBL] [Abstract][Full Text] [Related]
7. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
[TBL] [Abstract][Full Text] [Related]
8. Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats.
Van der Graaff D; Kwanten WJ; Couturier FJ; Govaerts JS; Verlinden W; Brosius I; D'Hondt M; Driessen A; De Winter BY; De Man JG; Michielsen PP; Francque SM
Lab Invest; 2018 Oct; 98(10):1263-1275. PubMed ID: 29326427
[TBL] [Abstract][Full Text] [Related]
9. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
10. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
12. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
13. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
[TBL] [Abstract][Full Text] [Related]
14. Experimental models of non-alcoholic fatty liver disease in rats.
Kucera O; Cervinkova Z
World J Gastroenterol; 2014 Jul; 20(26):8364-76. PubMed ID: 25024595
[TBL] [Abstract][Full Text] [Related]
15. Chronic intermittent hypoxia promotes early intrahepatic endothelial impairment in rats with nonalcoholic fatty liver disease.
Hernández-Bustabad A; Morales-Arraez D; González-Paredes FJ; Abrante B; Díaz-Flores F; Abreu-González P; de la Barreda R; Quintero E; Hernández-Guerra M
Am J Physiol Gastrointest Liver Physiol; 2022 Oct; 323(4):G362-G374. PubMed ID: 35916415
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease.
Gonzalez-Paredes FJ; Hernández Mesa G; Morales Arraez D; Marcelino Reyes R; Abrante B; Diaz-Flores F; Salido E; Quintero E; Hernández-Guerra M
PLoS One; 2016; 11(5):e0156650. PubMed ID: 27227672
[TBL] [Abstract][Full Text] [Related]
17. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
[TBL] [Abstract][Full Text] [Related]
19. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
20. Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers.
Honma M; Sawada S; Ueno Y; Murakami K; Yamada T; Gao J; Kodama S; Izumi T; Takahashi K; Tsukita S; Uno K; Imai J; Kakazu E; Kondo Y; Mizuno K; Kawagishi N; Shimosegawa T; Katagiri H
Int J Obes (Lond); 2018 Sep; 42(9):1544-1555. PubMed ID: 29717275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
